Company’s lead product candidate, ELA026, is in a clinical study for a life-threatening inflammatory disease, secondary hemophagocytic lymphohistiocytosis (sHLH)

Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies that target signal regulatory proteins (SIRP), announced today that the company will present three posters related to the company’s lead drug candidate, ELA026, at the American Society of Hematology (ASH) annual meeting being held in New Orleans, Louisiana, December 10-13, 2022.

With ELA026, Electra is taking a first-in-class approach to targeting SIRP to enable precise depletion of pathological immune cells. ELA026 is currently in Phase 1 clinical studies, including a Phase 1b trial in patients with secondary hemophagocytic lymphohistiocytosis (sHLH), a life-threatening inflammatory disease.

Details of the poster presentations are as follows:

Title: Characterization of ELA026, a clinical-stage monoclonal antibody that rapidly and potently depletes myeloid cells and T lymphocytes

Presenter: Sandip Panicker, PhD, Chief Scientific Officer, Electra Therapeutics

Session Date and Time: Monday, December 12, 2022, 6:00 PM – 8:00 PM

Location: Ernest N. Morial Convention Center, Hall D

Abstract Number: 3722

Title: Trial in progress: A phase 1b study of ELA026 in patients with secondary hemophagocytic lymphohistiocytosis (sHLH)

Presenter: Gary Patou, MD, Chief Medical Officer, Electra Therapeutics

Session Date and Time: Monday, December 12, 2022, 6:00 PM – 8:00 PM

Location: Ernest N. Morial Convention Center, Hall D

Abstract Number: 3730

Title: Identification and characterization of a retrospective cohort of secondary hemophagocytic lymphohistiocytosis (sHLH) patients in the US

Presenter: Catherine Broome, MD, Medstar Georgetown University Hospital

Session Date and Time: Sunday, December 11, 2022, 6:00 PM – 8:00 PM

Location: Ernest N. Morial Convention Center, Hall D

Abstract Number: 2415

About Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

Secondary hemophagocytic lymphohistiocytosis (sHLH) is a life-threatening hyperinflammatory condition for which there is no approved treatment. sHLH can be triggered by cancer, immunotherapy, infection, or an autoimmune disease. Once triggered, sHLH requires immediate intervention. Without treatment, it can rapidly progress from symptoms such as persistent fever, hepatomegaly and/or splenomegaly, and cytopenias, to multi-organ failure and death. Even with the current use of off-label treatments that have toxicity challenges and limited efficacy, sHLH remains fatal in approximately 60% of adults within 3.5 years.

About Electra Therapeutics

Electra Therapeutics is a clinical stage biotechnology company developing therapies that target signal regulatory proteins (SIRP) for the treatment of immunological diseases and cancer. Electra currently has one program in clinical development and additional preclinical programs. The company’s lead product candidate, ELA026, is a monoclonal antibody that targets SIRP on the cell surface of myeloid and T cells, and precisely depletes pathological immune cells. ELA026 is in clinical development for secondary hemophagocytic lymphohistiocytosis (sHLH), a life-threatening hyperinflammatory condition for which there is no approved treatment. For more information, please visit Electra Therapeutics and follow us on Twitter @ELECTRA_Biotech and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221103005259/en/